Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous AD-MSCs in Painful Degenerative Disc Disease
NCT03461458Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Oct 2018
- Primary completion
- Feb 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous adipose-derived mesenchymal stromal cells in degenerative disc disease (DDD) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Adverse Events at 2 years. Started Oct 2018; status: terminated.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT03461458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03461458.